Is SYRE or INSM more profitable?

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Spyre Therapeutics' return on equity of -42.88% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Insmed -144.44% -130.11% -51.57%

Does the media prefer SYRE or INSM?

In the previous week, Insmed had 7 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for Insmed and 6 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 1.50 beat Spyre Therapeutics' score of 0.07 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BNTX or SYRE?

In the previous week, BioNTech had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for BioNTech and 6 mentions for Spyre Therapeutics. BioNTech's average media sentiment score of 0.66 beat Spyre Therapeutics' score of 0.07 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SYRE or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Spyre Therapeutics. Roivant Sciences' average media sentiment score of 0.99 beat Spyre Therapeutics' score of 0.07 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRNA or SYRE?

In the previous week, Moderna had 23 more articles in the media than Spyre Therapeutics. MarketBeat recorded 29 mentions for Moderna and 6 mentions for Spyre Therapeutics. Moderna's average media sentiment score of 0.50 beat Spyre Therapeutics' score of 0.07 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spyre Therapeutics (SYRE) Competitors

$78.48 +4.96 (+6.75%)

Closing price 04:00 PM Eastern

Extended Trading

$82.00 +3.52 (+4.48%)

As of 07:04 PM Eastern

Compare

SYRE vs. INSM, BNTX, ROIV, VTRS, and MRNA

Should you buy Spyre Therapeutics stock or one of its competitors? MarketBeat compares Spyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyre Therapeutics include Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Spyre Therapeutics compare to Insmed?

Spyre Therapeutics (NASDAQ:SYRE) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Insmed had 7 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for Insmed and 6 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 1.50 beat Spyre Therapeutics' score of 0.07 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyre Therapeutics has higher earnings, but lower revenue than Insmed. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A
Insmed	$606.42M	37.50	-$1.28B	-$5.75	N/A

Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Spyre Therapeutics presently has a consensus price target of $91.33, suggesting a potential upside of 16.38%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 101.06%. Given Insmed's higher possible upside, analysts plainly believe Insmed is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Spyre Therapeutics' return on equity of -42.88% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Spyre Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market.

BioNTech presently has a consensus price target of $129.56, suggesting a potential upside of 44.62%. Spyre Therapeutics has a consensus price target of $91.33, suggesting a potential upside of 16.38%. Given BioNTech's higher probable upside, equities analysts plainly believe BioNTech is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioNTech had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for BioNTech and 6 mentions for Spyre Therapeutics. BioNTech's average media sentiment score of 0.66 beat Spyre Therapeutics' score of 0.07 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Spyre Therapeutics has lower revenue, but higher earnings than BioNTech. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.98	-$1.29B	-$5.88	N/A
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A

Summary

BioNTech beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Roivant Sciences?

Spyre Therapeutics (NASDAQ:SYRE) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Spyre Therapeutics currently has a consensus target price of $91.33, suggesting a potential upside of 16.38%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 13.75%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spyre Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A
Roivant Sciences	$8.26M	2,571.43	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Spyre Therapeutics. Roivant Sciences' average media sentiment score of 0.99 beat Spyre Therapeutics' score of 0.07 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Viatris?

Spyre Therapeutics (NASDAQ:SYRE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Spyre Therapeutics had 6 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Spyre Therapeutics and 0 mentions for Viatris. Viatris' average media sentiment score of 1.44 beat Spyre Therapeutics' score of 0.07 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyre Therapeutics	Neutral
Viatris	Positive

Spyre Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Viatris	-2.04%	19.04%	7.62%

Spyre Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A

Spyre Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Spyre Therapeutics currently has a consensus price target of $91.33, suggesting a potential upside of 16.38%. Viatris has a consensus price target of $16.43, suggesting a potential upside of 3.32%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Spyre Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Spyre Therapeutics beats Viatris on 12 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

75.3% of Moderna shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Moderna had 23 more articles in the media than Spyre Therapeutics. MarketBeat recorded 29 mentions for Moderna and 6 mentions for Spyre Therapeutics. Moderna's average media sentiment score of 0.50 beat Spyre Therapeutics' score of 0.07 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	11 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna presently has a consensus price target of $35.73, suggesting a potential downside of 30.74%. Spyre Therapeutics has a consensus price target of $91.33, suggesting a potential upside of 16.38%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market.

Spyre Therapeutics has lower revenue, but higher earnings than Moderna. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	10.53	-$2.82B	-$8.15	N/A
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Moderna on 11 of the 17 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRE vs. The Competition

Export

Metric	Spyre Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.82B	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-37.73	18.78	23.87	24.36
Price / Sales	7,657.53	320.80	521.52	117.06
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	10.88	6.80	9.99	6.73
Net Income	-$155.20M	$24.09M	$3.56B	$337.03M
7 Day Performance	8.83%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	375.06%	48.90%	28.76%	33.98%

Spyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRE Spyre Therapeutics	1.9131 of 5 stars	$78.48 +6.7%	$91.33 +16.4%	+343.7%	$6.82B	$890K	N/A	73	News Coverage Analyst Forecast Insider Trade
INSM Insmed	3.8095 of 5 stars	$108.89 +2.5%	$210.95 +93.7%	+42.1%	$23.60B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	3.7439 of 5 stars	$92.38 +0.3%	$128.44 +39.0%	-23.5%	$23.36B	$3.25B	N/A	7,807	Analyst Forecast
ROIV Roivant Sciences	2.881 of 5 stars	$29.64 -1.1%	$33.59 +13.3%	+155.3%	$21.21B	$8.26M	N/A	860	News Coverage Positive News Gap Down
VTRS Viatris	3.0441 of 5 stars	$16.24 -2.5%	$16.43 +1.2%	+78.3%	$18.91B	$14.30B	N/A	30,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Competitors

SYRE vs. INSM, BNTX, ROIV, VTRS, and MRNA

How does Spyre Therapeutics compare to Insmed?

Summary

How does Spyre Therapeutics compare to BioNTech?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Summary

How does Spyre Therapeutics compare to Viatris?

Summary

How does Spyre Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Competitors

SYRE vs. INSM, BNTX, ROIV, VTRS, and MRNA

How does Spyre Therapeutics compare to Insmed?

Does the media prefer SYRE or INSM?

Do insiders and institutionals hold more shares of SYRE or INSM?

Which has preferable earnings and valuation, SYRE or INSM?

Which has more volatility and risk, SYRE or INSM?

Do analysts prefer SYRE or INSM?

Is SYRE or INSM more profitable?

Summary

How does Spyre Therapeutics compare to BioNTech?

Which has more volatility and risk, BNTX or SYRE?

Do analysts rate BNTX or SYRE?

Do insiders & institutionals hold more shares of BNTX or SYRE?

Does the media prefer BNTX or SYRE?

Is BNTX or SYRE more profitable?

Which has preferable earnings & valuation, BNTX or SYRE?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Do analysts rate SYRE or ROIV?

Is SYRE or ROIV more profitable?

Which has more volatility and risk, SYRE or ROIV?

Do insiders & institutionals hold more shares of SYRE or ROIV?

Which has better valuation & earnings, SYRE or ROIV?

Does the media refer more to SYRE or ROIV?

Summary

How does Spyre Therapeutics compare to Viatris?

Do institutionals & insiders hold more shares of SYRE or VTRS?

Does the media prefer SYRE or VTRS?

Is SYRE or VTRS more profitable?

Which has preferable valuation & earnings, SYRE or VTRS?

Which has more risk and volatility, SYRE or VTRS?

Do analysts rate SYRE or VTRS?

Summary

How does Spyre Therapeutics compare to Moderna?

Do institutionals & insiders have more ownership in MRNA or SYRE?

Does the media refer more to MRNA or SYRE?

Do analysts rate MRNA or SYRE?

Which has more risk & volatility, MRNA or SYRE?

Which has stronger valuation and earnings, MRNA or SYRE?

Is MRNA or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools